Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:aims_to |
improve patient outcomes
reduce cardiovascular events |
| gptkbp:analyzes |
cost-effectiveness
quality of life measures biomarker data subgroup outcomes |
| gptkbp:can_involve |
interdisciplinary teams
patient engagement strategies multinational research teams patients with hypercholesterolemia |
| gptkbp:collaborates_with |
research institutions
|
| gptkbp:compare |
alirocumab to placebo
|
| gptkbp:conducted |
multiple countries
|
| gptkbp:contribution |
scientific knowledge
global health initiatives guidelines for cholesterol management clinical practice changes |
| gptkbp:enroll |
thousands of participants
|
| gptkbp:evaluates |
therapeutic strategies
quality of care patient adherence patient-reported outcomes impact on healthcare systems dosing regimens effectiveness of alirocumab impact on cardiovascular mortality real-world effectiveness safety of alirocumab |
| gptkbp:focus |
lipid-lowering therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
ODYSSEY trials
|
| gptkbp:include |
long-term follow-up
|
| gptkbp:influence |
clinical trial design
future research directions treatment guidelines |
| gptkbp:investigates |
comorbid conditions
|
| gptkbp:is_examined_in |
long-term safety
|
| gptkbp:is_funded_by |
gptkb:pharmaceuticals
|
| gptkbp:measures |
LDL cholesterol levels
|
| gptkbp:provides |
data for meta-analyses
evidence for reimbursement decisions |
| gptkbp:published_in |
medical journals
|
| gptkbp:recruitment |
high-risk cardiovascular patients
|
| gptkbp:report_results_on |
adverse events
|
| gptkbp:reports_to |
findings at conferences
clinical outcomes safety profiles |
| gptkbp:result |
peer-reviewed journals
|
| gptkbp:sponsor |
gptkb:Sanofi
|
| gptkbp:support |
regulatory submissions
patient education initiatives healthcare policy decisions clinical decision-making. |
| gptkbp:track |
treatment adherence
cholesterol levels over time |
| gptkbp:utilizes |
randomized controlled design
|
| gptkbp:was_a_demonstration_of |
benefits of PCSK9 inhibitors
|
| gptkbp:bfsParent |
gptkb:Praluent
|
| gptkbp:bfsLayer |
5
|